Fertility control by continuous administration of d-Norgestrel, 0.03 mg.
D000293:Adolescent; D000328:Adult; D001706:Biopsy; D002464:Cell Migration Inhibition; D002582:Cervix Mucus; D002584:Cervix Uteri / Q000187:drug effects; D003267:Contraception; D004361:Drug Tolerance; D004717:Endometrium / Q000033:anatomy & histology; D005260:Female; D005298:Fertility / Q000187:drug effects*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008598:Menstruation / Q000187:drug effects; D009644:Norgestrel / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D010053:Ovary / Q000502:physiology; D010060:Ovulation; D011247:Pregnancy; D011275:Pregnancy, Unwanted; D011276:Pregnanediol / Q000652:urine; D013094:Spermatozoa; D014621:Vagina / Q000166:cytology; D014626:Vaginal Smears
D009644:Norgestrel; D007986:Luteinizing Hormone; D011276:Pregnanediol